ARQT on Nasdaq
Arcutis Biotherapeutics, Inc.
In its 2026 annual report the company says: “We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions.”4 It is headquartered in Westlake Village, California.1 Its shares trade on Nasdaq under the symbol ARQT.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Sinovac Biotech, Atea Pharmaceuticals, Inc. or Esperion Therapeutics, or pick any stock.
- TickerARQT on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersWestlake Village, California1
- Incorporated inDE2
- Business address3027 Townsgate Road, Suite 300, Westlake Village, Ca 913612
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions. We believe we have built a leading platform for dermatologic product development and commercialization. Our strategy is to focus on validated biological targets, and to use our drug development platform and deep dermatology expertise to develop and commercialize differentiated products that have the potential to address the major shortcomings of existing therapies in our targeted indications. We believe this strategy uniquely positions us to rapidly advance our goal of bridging the treatment innovation gap in dermatology, while maximizing our pro…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-3.3%Operating margin5
-4.3%Net margin5
91.3%Revenue growth, 20255
-8.5%Return on equity5
0.57×Debt to equity5
-$6.3MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
ZORYVE Foam brought in 49% of the revenue Arcutis Biotherapeutics, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| ZORYVE Foam | $0 | $71.5M | $181.9M |
| ZORYVE Cream 0.3% | $29.2M | $85.1M | $121.0M |
| ZORYVE Cream 0.15% | $0 | $9.9M | $68.3M |
| ZORYVE cream 0.05% | $0 | $0 | $911.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue9¢$36.7M
- Research and development20¢$77.1M
- Selling, general and admin70¢$274.6M
- Income tax0¢$1.2M
Out of $376.1M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Product revenue, net | $372.1M | $166.5M | $29.2M |
| Other revenue | $4.0M | $30.0M | $30.4M |
| Total revenues | $376.1M | $196.5M | $59.6M |
| Cost of sales | $36.7M | $19.1M | $5.0M |
| Research and development | $77.1M | $76.4M | $110.6M |
| Selling, general and administrative | $274.6M | $229.4M | $185.1M |
| Total operating expenses | $388.3M | $324.9M | $300.7M |
| Loss from operations | -$12.2M | -$128.4M | -$241.1M |
| Interest income | $8.9M | $16.1M | $12.5M |
| Interest expense | -$12.1M | -$27.2M | -$29.7M |
| Other income (expense), net | $443.0K | $47.0K | -$731.0K |
| Loss before income taxes | -$15.0M | -$139.4M | -$259.0M |
| Provision for income taxes | $1.2M | $647.0K | $3.1M |
| Net loss | -$16.1M | -$140.0M | -$262.1M |
| Unrealized gain on marketable securities | -$206.0K | $219.0K | $1.2M |
| Foreign currency translation adjustment | $169.0K | -$230.0K | -$96.0K |
| Total other comprehensive income (loss) | -$37.0K | -$11.0K | $1.1M |
| Comprehensive loss | -$16.2M | -$140.1M | -$261.1M |
| Net loss per share, basic (in USD per share) | -$0.13 | -$1.16 | -$3.78 |
| Net loss per share, diluted (in USD per share) | -$0.13 | -$1.16 | -$3.78 |
| Weighted-average shares used in computing net loss per share, basic (in shares) | 127.2M shares | 121.0M shares | 69.3M shares |
| Weighted-average shares used in computing net loss per share, diluted (in shares) | 127.2M shares | 121.0M shares | 69.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $42.9M | $71.3M | ||
| Restricted cash | $308.0K | $617.0K | ||
| Marketable securities | $178.1M | $156.6M | ||
| Trade receivables, net | $146.2M | $73.1M | ||
| Inventory | $22.6M | $14.5M | ||
| Prepaid expenses and other current assets | $21.1M | $19.7M | ||
| Total current assets | $411.2M | $335.8M | ||
| Property, plant, and equipment, net | $1.0M | $1.0M | ||
| Intangible assets, net | $14.8M | $9.5M | ||
| Operating lease right-of-use asset | $4.5M | $2.0M | ||
| Other assets | $1.4M | $596.0K | ||
| Total assets | $433.0M | $348.9M | ||
| Accounts payable | $12.5M | $14.2M | ||
| Current portion of long-term debt, net | $1.0M | $0 | ||
| Accrued and other current liabilities | $116.3M | $66.8M | ||
| Total current liabilities | $129.8M | $81.0M | ||
| Operating lease liability, long-term | $5.3M | $2.6M | ||
| Long-term debt, net | $108.0M | $107.2M | ||
| Other long-term liabilities | $431.0K | $570.0K | ||
| Total liabilities | $243.5M | $191.3M | ||
| Common stock, $0.0001 par value; 300,000,000 shares authorized; 123,332,672 and 117,848,033 shares issued and outstanding at December 31, 2025 and 2024, respectively | $12.0K | $12.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive loss | -$44.0K | -$7.0K | ||
| Accumulated deficit | -$1.1B | -$1.1B | ||
| Total stockholders equity | $189.5M | $157.5M | $88.7M | $209.6M |
| Total liabilities and stockholders equity | $433.0M | $348.9M | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | ||
| Common stock, shares, issued (in shares) | 123.3M shares | 117.8M shares | ||
| Common stock, shares outstanding (in shares) | 123.3M shares | 117.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $42.9M | $71.3M | ||
| Restricted cash | $308.0K | $617.0K | ||
| Marketable securities | $178.1M | $156.6M | ||
| Trade receivables, net | $146.2M | $73.1M | ||
| Inventory | $22.6M | $14.5M | ||
| Prepaid expenses and other current assets | $21.1M | $19.7M | ||
| Total current assets | $411.2M | $335.8M | ||
| Property, plant, and equipment, net | $1.0M | $1.0M | ||
| Intangible assets, net | $14.8M | $9.5M | ||
| Operating lease right-of-use asset | $4.5M | $2.0M | ||
| Other assets | $1.4M | $596.0K | ||
| Total assets | $433.0M | $348.9M | ||
| Accounts payable | $12.5M | $14.2M | ||
| Current portion of long-term debt, net | $1.0M | $0 | ||
| Accrued and other current liabilities | $116.3M | $66.8M | ||
| Total current liabilities | $129.8M | $81.0M | ||
| Operating lease liability, long-term | $5.3M | $2.6M | ||
| Long-term debt, net | $108.0M | $107.2M | ||
| Other long-term liabilities | $431.0K | $570.0K | ||
| Total liabilities | $243.5M | $191.3M | ||
| Common stock, $0.0001 par value; 300,000,000 shares authorized; 123,332,672 and 117,848,033 shares issued and outstanding at December 31, 2025 and 2024, respectively | $12.0K | $12.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive loss | -$44.0K | -$7.0K | ||
| Accumulated deficit | -$1.1B | -$1.1B | ||
| Total stockholders equity | $189.5M | $157.5M | $88.7M | $209.6M |
| Total liabilities and stockholders equity | $433.0M | $348.9M | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | ||
| Common stock, shares, issued (in shares) | 123.3M shares | 117.8M shares | ||
| Common stock, shares outstanding (in shares) | 123.3M shares | 117.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$16.1M | -$140.0M | -$262.1M |
| Stock-based compensation expense | $40.4M | $41.7M | $38.8M |
| Amortization of intangible assets | $4.7M | $2.0M | $750.0K |
| Non-cash interest expense | $1.8M | $5.4M | $4.0M |
| Net accretion on marketable securities | -$2.1M | -$6.9M | -$7.0M |
| Other non-cash items, net | $652.0K | $769.0K | $2.0M |
| Accounts receivable, net | -$73.2M | -$47.3M | -$17.3M |
| Inventories | -$7.3M | -$400.0K | -$5.6M |
| Prepaid expenses and other current assets | -$2.0M | -$948.0K | -$8.6M |
| Accounts payable | -$1.7M | $2.2M | $3.2M |
| Accrued liabilities | $50.0M | $32.0M | $5.6M |
| Operating lease liabilities | -$680.0K | -$735.0K | -$657.0K |
| Net cash used in operating activities | -$5.6M | -$112.2M | -$247.1M |
| Purchases of marketable securities | -$247.0M | -$254.8M | -$225.8M |
| Proceeds from maturities and sales of marketable securities | $227.4M | $288.8M | $406.5M |
| Purchases of property and equipment | -$686.0K | -$143.0K | -$428.0K |
| Milestone payment for intangible asset | -$10.0M | -$5.0M | $0 |
| Net cash provided by (used in) investing activities | -$30.3M | $28.8M | $180.2M |
| Proceeds from issuance of common stock, net of issuance costs | $0 | $161.7M | $0 |
| Repayment of long-term debt | $0 | -$100.0M | $0 |
| Proceeds from issuance of common stock upon exercise of stock options | $4.6M | $2.8M | $1.2M |
| Proceeds from issuance of common stock for ESPP | $2.4M | $1.7M | $1.2M |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | $0 | $0 | $95.8M |
| Proceeds from issuance of shares under ATM, net of issuance costs | $0 | $0 | $3.1M |
| Net cash provided by financing activities | $7.0M | $66.2M | $101.3M |
| Effect of exchange rate changes on cash | $168.0K | -$235.0K | -$50.0K |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$28.7M | -$17.4M | $34.4M |
| Right-of-use assets obtained in exchange for operating lease liabilities | $2.9M | $0 | $0 |
| Interest expense paid in cash | $10.3M | $22.2M | $25.4M |
No quarter-by-quarter statement was filed.
Corporate structure
Arcutis Biotherapeutics, Inc. sits at the top of its group. 3 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Arcutis Biotherapeutics, Inc.
- BlackRock Filed SCHEDULE 13G/A on Arcutis Biotherapeutics, Inc., latest Oct 5, 2026 (7 filings since Feb 3, 2022)
- Polar Capital Holdings Plc Filed SCHEDULE 13G on Arcutis Biotherapeutics, Inc., latest Aug 14, 2026 (5 filings since Nov 16, 2023)
- State Street Corporation Filed SCHEDULE 13G on Arcutis Biotherapeutics, Inc., latest Aug 7, 2026 (4 filings since Feb 8, 2023)
- Prudential Financial Filed SCHEDULE 13G/A on Arcutis Biotherapeutics, Inc., latest May 8, 2026 (5 filings since Nov 9, 2023)
- JENNISON ASSOCIATES LLC Filed SCHEDULE 13G/A on Arcutis Biotherapeutics, Inc., latest May 6, 2026 (6 filings since Feb 8, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Arcutis Biotherapeutics, Inc., latest Mar 26, 2026 (2 filings since Feb 13, 2024)
- Rubric Capital Management LP Filed SCHEDULE 13G/A on Arcutis Biotherapeutics, Inc., latest Feb 13, 2026 (3 filings since Feb 12, 2024)
- Frazier Life Sciences VIII, L.P. Filed SCHEDULE 13D/A on Arcutis Biotherapeutics, Inc., latest Aug 20, 2025 (4 filings since Aug 9, 2022)
- Point72 Asset Management, L.P. Filed SC 13G/A on Arcutis Biotherapeutics, Inc., latest Nov 14, 2024 (5 filings since Dec 15, 2021)
- Morgan Stanley Filed SC 13G/A on Arcutis Biotherapeutics, Inc., latest Nov 6, 2024 (2 filings since Feb 12, 2024)
- MONTANOVA CAPITAL, LLC Filed SC 13G/A on Arcutis Biotherapeutics, Inc., latest Feb 13, 2024 (2 filings since Oct 30, 2023)
- FMR LLC Filed SC 13G/A on Arcutis Biotherapeutics, Inc., latest Nov 13, 2023 (3 filings since Feb 9, 2022)
- Arcutis Biotherapeutics, Inc. Westlake Village, California
- Arcutis Canada, Inc. Subsidiary · Canada
- Ducentis Biotherapeutics Ltd. Subsidiary · United Kingdom
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Arcutis Biotherapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $4.3M5 Dec 31, 2025 | $3.6M5 Dec 31, 2024 | +19.0% |
| Accumulated depreciation | $3.2M5 Dec 31, 2025 | $2.6M5 Dec 31, 2024 | +26.7% |
| Property and equipment, net | $1.0M5 Dec 31, 2025 | $1.0M5 Dec 31, 2024 | +0.2% |
| Operating-lease assets (leased space) | $4.5M5 Dec 31, 2025 | $2.0M5 Dec 31, 2024 | +128.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $42.9M5 Dec 31, 2025 | $71.3M5 Dec 31, 2024 | −39.9% |
| Marketable securities, current | $178.1M5 Dec 31, 2025 | $156.6M5 Dec 31, 2024 | +13.7% |
| Debt securities available for sale | $178.1M5 Dec 31, 2025 | $156.6M5 Dec 31, 2024 | +13.7% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $14.8M5 Dec 31, 2025 | $9.5M5 Dec 31, 2024 | +56.3% |
| Finite-lived intangibles, net | $14.8M5 Dec 31, 2025 | $9.5M8 Dec 31, 2024 | +56.3% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $22.6M5 Dec 31, 2025 | $14.5M5 Dec 31, 2024 | +55.8% |
| Raw materials | $5.0M5 Dec 31, 2025 | $4.3M5 Dec 31, 2024 | +17.4% |
| Work in process | $5.0M5 Dec 31, 2025 | $584.0K5 Dec 31, 2024 | +761.8% |
| Finished goods | $12.6M5 Dec 31, 2025 | $9.6M5 Dec 31, 2024 | +30.2% |
Properties, in its own words
Our corporate headquarters is located in Westlake Village, California, where we lease 22,643 square feet of office space.
Item 2 of the 10-K filed Feb 25, 2026.4
Leadership
Who has led Arcutis Biotherapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerTodd Franklin Watanabe Feb 4, 2020 to Oct 11, 202213
- PresidentTodd Franklin Watanabe Feb 4, 2020 to Oct 11, 202213
- Chief financial officerLatha Vairavan May 7, 2025 to now14
- Chief financial officerDavid Joseph Topper Apr 11, 2024 to May 7, 202515
- Chief financial officerScott L. Burrows Apr 5, 2021 to Mar 8, 202316
- Chief financial officerJohn W. Smither Jan 30, 2020 to Feb 15, 202417
Board members and other officers (25)
- OfficerTodd Franklin Watanabe Nov 9, 2022 to now18
- See RemarkMasaru Matsuda Nov 22, 2022 to now19
- Chief Technical OfficerDavid W. Osborne Jan 30, 2020 to Mar 8, 202320
- Chief Medical OfficerHoward G. Welgus Jan 30, 2020 to Mar 16, 202021
- Chief Commercial OfficerKenneth A. Lock Jan 30, 2020 to Mar 8, 202322
- Senior VP, ManufacturingPatricia A. Turney Jan 30, 2020 to Mar 8, 202323
- OfficerPatrick Burnett Aug 5, 2020 to now24
- Board memberChristopher Peetz Jul 17, 2026 to now25
- Board memberAmit Munshi Dec 8, 2025 to now26
- Board memberNeha Krishnamohan Sep 6, 2022 to now27
- Board memberSue-Jean Lin Jun 16, 2021 to now28
- Board memberKeith R. Leonard Sep 7, 2021 to now29
- Board memberAlexander Asam Jan 30, 2020 to Jan 30, 202030
- Board memberBhaskar Chaudhuri Jan 30, 2020 to now31
- Board memberDaniel Estes Jan 30, 2020 to Mar 3, 202032
- Board memberJonathan Silverstein Jan 30, 2020 to Oct 6, 202033
- Board memberJoseph L. Turner Jan 30, 2020 to Jun 3, 202234
- Board memberPatrick J. Heron Jan 30, 2020 to now35
- Board memberRicky Sun Jan 30, 2020 to Jun 11, 202136
- Board memberTodd Franklin Watanabe Jan 30, 2020 to now37
- Board memberJohn W. Smither Mar 3, 2020 to Mar 3, 202038
- Board memberHalley E. Gilbert May 1, 2020 to now39
- Board memberHoward G. Welgus Aug 5, 2020 to now40
- Board memberTerrie Curran Nov 4, 2020 to now41
- General counselMasaru Matsuda Jan 5, 2022 to Jun 2, 202242
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Arcutis, Inc.Sep 9, 2019 to Sep 9, 20192
Timeline
- Aug 5, 20268-K Results of operations; Executive or director change43
- Jul 16, 20268-K Executive or director change; Regulation FD disclosure44
- Jun 9, 20268-K Shareholder vote; Other events45
- May 6, 20268-K Financial statements and exhibits46
- Feb 25, 20268-K Results of operations47
- Dec 8, 20258-K Executive or director change; Regulation FD disclosure48
- Oct 28, 20258-K Results of operations49
- Aug 6, 20258-K Results of operations50
- Jun 17, 20258-K Shareholder vote; Other events51
- May 6, 20258-K Results of operations52
- Apr 10, 20258-K Executive or director change; Regulation FD disclosure53
- Feb 25, 20258-K Results of operations54
- Feb 4, 2020New chief executive Todd Franklin Watanabe becomes CEO13
Calendar
Coming up
- Oct 27, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.06 a share, on Oct 28, 2025.55
When it reported results
- Aug 5, 2026Reported quarterly or annual results43
- Feb 25, 2026Reported quarterly or annual results47
- Oct 28, 2025Reported quarterly or annual results49
- Aug 6, 2025Reported quarterly or annual results50
- May 6, 2025Reported quarterly or annual results52
- Feb 25, 2025Reported quarterly or annual results54
- Jan 13, 2025Reported quarterly or annual results56
- Nov 6, 2024Reported quarterly or annual results57
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
623 filings to the SEC since October 2021: 7 annual reports, 18 quarterly reports, 50 major events, 297 insider forms, 54 large holders, 197 other. The latest 20:
- Oct 15, 2026144 EDGAR
- Oct 5, 2026SCHEDULE 13G/A EDGAR
- Sep 18, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 16, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 10, 20264 EDGAR
- Sep 8, 2026144 EDGAR
- Aug 28, 20264 EDGAR
- Aug 27, 2026144 EDGAR
- Aug 24, 20264 EDGAR
- Aug 21, 20264 EDGAR
- Aug 20, 2026144 EDGAR
- Aug 19, 20264 EDGAR
- Aug 19, 2026144 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 13, 20264 EDGAR
- Aug 11, 2026144 EDGAR
- Aug 7, 2026SCHEDULE 13G EDGAR
The 623 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
245 open-market trades by officers, directors and large owners since October 2021: 18 buys and 227 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Matsuda MasaruSee Remarks | Sale | 3,674 | $25.00 | $91.8K | Form 4 |
| Sep 15, 2026 | Welgus Howard G.Director | Sale | 4,730 | $24.18 | $114.4K | Form 4 |
| Sep 8, 2026 | Matsuda MasaruSee Remarks | Sale | 9,989 | $25.03 | $250.0K | Form 4 |
| Aug 27, 2026 | Curran TerrieDirector | Sale | 38,200 | $25.03 | $956.1K | Form 4 |
| Aug 20, 2026 | Curran TerrieDirector | Sale | 1,072 | $26.04 | $27.9K | Form 4 |
| Aug 19, 2026 | Burnett PatrickSee Remarks | Sale | 1,697 | $27.00 | $45.8K | Form 4 |
| Aug 17, 2026 | Welgus Howard G.Director | Sale | 4,730 | $26.18 | $123.8K | Form 4 |
| Aug 12, 2026 | Burnett PatrickSee Remarks | Sale | 6,700 | $26.08 | $174.7K | Form 4 |
| Aug 11, 2026 | Burnett PatrickSee Remarks | Sale | 8,300 | $26.52 | $220.1K | Form 4 |
| Aug 3, 2026 | Burnett PatrickSee Remarks | Sale | 955 | $26.12 | $24.9K | Form 4 |
| Aug 3, 2026 | Matsuda MasaruSee Remarks | Sale | 1,230 | $26.12 | $32.1K | Form 4 |
| Aug 3, 2026 | Watanabe ToddSee Remarks | Sale | 4,375 | $26.12 | $114.3K | Form 4 |
| Jul 15, 2026 | Welgus Howard G.Director | Sale | 4,730 | $26.91 | $127.3K | Form 4 |
| Jun 17, 2026 | Welgus Howard G.Director | Sale | 635 | $25.67 | $16.3K | Form 4 |
| Jun 15, 2026 | LIN SUE-JEANDirector | Sale | 4,946 | $24.38 | $120.6K | Form 4 |
| Jun 15, 2026 | Welgus Howard G.Director | Sale | 4,096 | $24.41 | $100.0K | Form 4 |
| May 11, 2026 | Vairavan LathaSVP Chief Financial Officer | Sale | 435 | $21.05 | $9.2K | Form 4 |
| May 11, 2026 | Burnett PatrickSee Remarks | Sale | 222 | $21.05 | $4.7K | Form 4 |
| May 4, 2026 | Vairavan LathaSVP Chief Financial Officer | Sale | 1,341 | $23.61 | $31.7K | Form 4 |
| May 4, 2026 | Watanabe ToddSee Remarks | Sale | 3,172 | $23.61 | $74.9K | Form 4 |
All 245 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BlackRockSCHEDULE 13G/A, 7 filings Feb 3, 2022 to Oct 5, 202658
- Polar Capital Holdings PlcSCHEDULE 13G, 5 filings Nov 16, 2023 to Aug 14, 202659
- State Street CorporationSCHEDULE 13G, 4 filings Feb 8, 2023 to Aug 7, 202660
- Prudential FinancialSCHEDULE 13G/A, 5 filings Nov 9, 2023 to May 8, 202661
- JENNISON ASSOCIATES LLCSCHEDULE 13G/A, 6 filings Feb 8, 2024 to May 6, 202662
- VANGUARD GROUP INCSCHEDULE 13G/A, 2 filings Feb 13, 2024 to Mar 26, 202663
- Rubric Capital Management LPSCHEDULE 13G/A, 3 filings Feb 12, 2024 to Feb 13, 202664
- Frazier Life Sciences VIII, L.P.SCHEDULE 13D/A, 4 filings Aug 9, 2022 to Aug 20, 202565
- Point72 Asset Management, L.P.SC 13G/A, 5 filings Dec 15, 2021 to Nov 14, 202466
- Morgan StanleySC 13G/A, 2 filings Feb 12, 2024 to Nov 6, 202467
- MONTANOVA CAPITAL, LLCSC 13G/A, 2 filings Oct 30, 2023 to Feb 13, 202468
- FMR LLCSC 13G/A, 3 filings Feb 9, 2022 to Nov 13, 202369
- ORBIMED ADVISORS LLCSC 13D/A, 4 filings Apr 8, 2022 to Aug 26, 202270
- Bain Capital Life Sciences Fund, L.P.SC 13D/A, 2 filings May 27, 2022 to Aug 8, 202271
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Todd Franklin Watanabe | 58 | $713.3K | $7.2M72 |
| 2025 | L. Todd Edwards | 62 | $535.0K | $3.0M72 |
| 2025 | Patrick E. Burnett, | $535.0K | $3.0M72 | |
| 2025 | Masaru MatsudaJ.D. | $495.2K | $2.1M72 | |
| 2025 | David Topper | $196.5K | $1.9M72 | |
| 2025 | Latha Vairavan | 48 | $419.5K | $1.9M72 |
| 2024 | Former Chief Financial Officer | $364.8K | $5.3M72 | |
| 2024 | President and Chief | $660.9K | $3.7M72 | |
| 2024 | Chief Commercial Officer | $516.4K | $2.0M72 | |
| 2024 | Chief Legal Officer | $465.5K | $1.7M72 | |
| 2023 | Executive Officer | $633.5K | $4.9M72 | |
| 2023 | Chief Medical Officer | $477.3K | $1.7M72 | |
| 2023 | Chief Legal Officer | $434.0K | $1.6M72 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Montanova Capital, LLC | 12,437,000 | $326.1M | 6.9% | +110,000 |
| BlackRock, Inc. | 10,545,466 | $276.5M | 0.0% | +1,345,055 |
| Frazier Life Sciences Management, L.P. | 9,874,511 | $258.9M | 5.6% | No change |
| Rubric Capital Management LP | 8,271,577 | $216.9M | 2.0% | No change |
| Polar Capital Holdings Plc | 6,606,945 | $173.2M | 0.5% | +940,005 |
| State Street Corp | 5,822,840 | $152.7M | 0.0% | −473,357 |
| Vanguard Capital Management LLC | 4,988,756 | $130.8M | 0.0% | +117,220 |
| Morgan Stanley | 4,451,014 | $116.7M | 0.0% | +232,083 |
| Jennison Associates LLC | 4,219,058 | $110.6M | 0.1% | −761,712 |
| D. E. Shaw & Co., Inc. | 3,949,609 | $103.6M | 0.1% | +1,453,387 |
| UBS Group AG | 3,333,015 | $87.4M | 0.0% | +3,791 |
| Bank Of America Corp /de/ | 2,987,431 | $78.3M | 0.0% | +766,142 |
| Geode Capital Management, LLC | 2,982,446 | $78.2M | 0.0% | −62,860 |
| Vanguard Portfolio Management LLC | 2,429,005 | $63.7M | 0.0% | +474,320 |
| Orbimed Advisors LLC | 2,042,000 | $53.5M | 1.0% | New |
| Franklin Resources Inc | 1,930,982 | $50.6M | 0.0% | −366,961 |
| American Century Companies Inc | 1,925,031 | $50.5M | 0.0% | +461,803 |
| Goldman Sachs Group Inc | 1,668,367 | $43.7M | 0.0% | +65,354 |
| Jupiter Topco LLC | 1,410,435 | $37.0M | 0.0% | New |
| Oberweis Asset Management Inc/ | 1,372,941 | $36.0M | 0.7% | +7,000 |
| Gilder Gagnon Howe & Co LLC | 1,313,211 | $34.4M | 0.4% | −2,990,799 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,265,283 | $33.2M | 10.8% | −90,609 |
| Bamco Inc /ny/ | 1,253,120 | $32.9M | 0.0% | +180,931 |
| Citadel Advisors LLC | 1,160,014 | $30.4M | 0.0% | +1,144,408 |
| Federated Hermes, Inc. | 1,124,629 | $29.5M | 0.0% | +47,362 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
6 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| May 29, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +32.3% | Report |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +8.7% | Report |
| Dec 11, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Partial sale | $1,001 - $15,000 | +14.2% | Report |
| Sep 15, 2023 | Josh GottheimerDemocratic, House | Sale | $1,001 - $15,000 | −249.1% | Report |
| Apr 17, 2023 | Josh GottheimerDemocratic, House | Buy | $1,001 - $15,000 | +19.7% | Report |
| Jun 15, 2022 | Josh GottheimerDemocratic, House | Buy | $1,001 - $15,000 | −63.3% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Arcutis Biotherapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARArcutis Biotherapeutics, Inc.1
- CIK0001787306
- Employer ID (EIN)81-29742554
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address3027 Townsgate Road, Suite 300, Westlake Village, CA 913611
- Phone805-418-50061
- Shares outstanding125,691,961 as of Jul 31, 202611
- Public float$1.5B as of Jun 30, 20254
- AuditorErnst & Young LLP, Los Angeles, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceSep 9, 20191
- Filings849 in all: 4 (392), 144 (153), 8-K (72), 3 (31), 10-Q (20), SC 13G/A (19), SC 13D/A (15), 4/A (14)1
All 44 form types
SC 13G (13), SCHEDULE 13G/A (12), UPLOAD (11), 424B5 (10), CORRESP (10), S-8 (8), 10-K (7), DEF 14A (6), DEFA14A (6), 10-Q/A (3), 5 (3), ARS (3), DRS/A (3), EFFECT (3), SC 13D (3), SCHEDULE 13G (3), 10-K/A (2), 3/A (2), 424B4 (2), DRS (2), DRSLTR (2), S-1 (2), S-3ASR (2), SC TO-I/A (2), SEC STAFF LETTER (2), 144/A (1), 8-A12B (1), 8-K/A (1), CERT (1), D (1), S-1/A (1), S-1MEF (1), S-3 (1), SC TO-C (1), SC TO-I (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Feb 25, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 21, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.0001 | ARQT | The Nasdaq Global Select Market |
From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Arcutis Biotherapeutics, Inc. names in Item 1A of its 10-K filed Feb 25, 2026: 73 risks under these headings, as written.4
- Risks Related to Our Limited Operating History, Financial Condition, and Capital Requirements
- We are a commercial-stage biopharmaceutical company with four products approved for commercial sale. We have incurred significant losses since our inception and could incur losses in the future, which, together with our limited history as a commercial-stage company, makes it difficult to assess our future viability.
- Due to the ongoing commercialization of products approved for commercial sale, and our development strategy and continued development of our pipeline of product candidates through clinical trials, our capital requirements are difficult to predict and may change. We may require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital if or when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate certain operations or efforts.
- Our operating results may fluctuate significantly, which makes our future operating results difficult to predict, and could cause our future operating results to fall below expectations.
- Our estimated market opportunities are subject to numerous uncertainties and may prove to be inaccurate. If we have overestimated the size of our market opportunities, our future growth may be limited.
- The terms of our loan and security agreement require us to meet certain operating and financial covenants, and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
- Changes in corporate governance policies and practices may impact our business.
- Risks Related to Development and Commercialization
- The sales, marketing, and distribution of ZORYVE or any future approved products may be unsuccessful or less successful than anticipated.
- Our business is dependent on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of our current product candidates.
- Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payers, or others in the medical community necessary for commercial success.
- If we are unable to achieve and maintain third-party payer coverage and adequate levels of reimbursement for ZORYVE or any of our product candidates for which we receive regulatory approval, or any future products we may seek to commercialize, their commercial success may be severely hindered.
The other 62 risks
- Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
- We may be unable to obtain regulatory approval for an expansion of our product labels or approval of our product candidates under applicable regulatory requirements. The denial or delay of any such approval would prevent or delay commercialization of additional indications or our product candidates and adversely impact our potential to generate revenue, our business, and our results of operations.
- Topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- Certain of the endpoints in our planned clinical trials rely on a subjective assessment of the effect of the product candidate in the subject by either the physician or patient, and may prove difficult to meet in patients with more severe disease, which exposes us to a variety of risks for the successful completion of our clinical trials.
- Enrollment and retention of subjects in clinical trials is expensive and time-consuming and may result in additional costs and delays in our product development activities, or in the failure of such activities.
- Serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs, or necessitate the abandonment or limitation of the development of some of our product candidates.
- As a company, we have obtained marketing approval for only four products and we may be unable to successfully obtain marketing approval in a timely manner, or at all, for any of our other product candidates.
- We may choose not to continue developing or commercializing ZORYVE or any of our product candidates at any time during development or after approval, which would reduce or eliminate our potential return on investment for ZORYVE, and our product candidates.
- If we seek to market products in countries other than the United States or Canada, we will need to comply with the regulations of each country in which we seek to market our products.
- Our license agreements and share purchase agreement with Ducentis Biotherapeutics obligate us to make certain milestone and royalty payments, some of which have been or will be triggered prior to commercialization of the applicable product candidates.
- We face significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications, and our operating results will suffer if we fail to compete effectively.
- Risks Related to Our Business and Operations
- We may need to increase the size of our organization, and we may experience difficulties in executing our growth strategy, managing any growth, and retaining talent.
- If we are not successful in acquiring, developing, and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.
- Our current and future collaboration arrangements may not be successful, which could adversely affect our ability to develop and commercialize future product candidates.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of ZORYVE or our current or future product candidates.
- If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could undermine the credibility of our operating results, harm investors’ views of us and, as a result, the value of our common stock.
- Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.
- We depend on our information technology systems, and any failure of these systems, including due to the use of artificial intelligence (AI), or those of our CROs or other contractors or consultants we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations, financial condition, and prospects.
- Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.
- Failure to comply with anti-corruption and anti-money laundering laws, including the FCPA and similar laws associated with our activities outside of the United States, as well as export and import controls, customs, and economic and trade sanctions laws, could subject us to penalties and other adverse consequences.
- Our commercial partners, as well as our employees and independent contractors, including principal investigators, consultants, suppliers, service providers, and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.
- Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
- Risks Related to Our Reliance on Third Parties
- We rely on third-party manufacturers to manufacture nonclinical, clinical and commercial supplies of ZORYVE and our product candidates. The loss of these manufacturers or their sub-suppliers, or their failure to provide us with sufficient quantities at acceptable quality levels, or at all, would materially and adversely affect our business.
- If our third-party manufacturers fail to comply with manufacturing or other regulations, our financial results and financial condition will be adversely affected.
- We rely on third parties to conduct our nonclinical studies and our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.
- Risks Related to Intellectual Property
- We may not be able to obtain, maintain or enforce patent rights or other intellectual property rights that cover ZORYVE or our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.
- We may become subject to claims alleging infringement of third parties’ patents or proprietary rights and/or claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development and commercialization of ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE cream 0.05%, ZORYVE foam, ARQ-234, or any other product candidates.
- We may be subject to claims by third parties asserting that we, our employees or our licensors have misappropriated their intellectual property, including trade secrets, or claiming ownership of what we regard as our own intellectual property.
- The validity, scope, and enforceability of any patents listed in the Orange Book that cover ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE Cream 0.05%, or ZORYVE foam can be challenged by competitors.
- If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term of ZORYVE or our product candidates, our business may be materially harmed.
- Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.
- We may need to license additional intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
- We may not be able to protect our intellectual property rights throughout the world.
- Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- We will require final regulatory approval of, and registered trademarks for, any commercial tradename and registered trademarks for a commercial trade name for our product candidates in the United States or foreign jurisdictions and failure to secure such approval in a timely fashion could adversely affect our business.
- If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.
- If we fail to comply with our obligations under any license, collaboration, or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates.
- We may become involved in lawsuits to protect or enforce our patents, or other intellectual property or the patents of our licensors, which could be expensive and time-consuming.
- Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of any of our product candidates.
- Risks Related to Government Regulation
- Even if we receive regulatory approval of our product candidates, we will be subject to extensive and ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
- Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or policy changes could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.
- We may be subject to health care laws and regulations relating to our business, and could face substantial penalties if we are determined not to have fully complied with such laws, which would have an adverse impact on our business.
- We have conducted and may in the future conduct clinical trials for ZORYVE and our product candidates outside the United States and the FDA and applicable foreign regulatory authorities may not accept data from such trials.
- Recently enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize ZORYVE and to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
- If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, results of operations and financial condition.
- If ZORYVE or any of our product candidates that are approved for marketing are found to have been improperly promoted for off-label uses by us, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.
- Risks Related to Our Common Stock
- Raising additional funds by issuing securities may cause dilution to existing stockholders, raising additional funds through debt financings may involve restrictive covenants, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.
- Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
- Our ability to utilize our net operating loss carryforwards and research and development income tax credit carryforwards may be limited.
- Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.
- Our restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.
- General Risk Factors
- Macroeconomic factors, including unfavorable or uncertain global and regional economic, political and health conditions, could adversely affect our business, financial condition or results of operations.
- The stock price of our common stock may be volatile or may decline.
- If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
- If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop our current and any future product candidates, commercialize ZORYVE or our product candidates or otherwise implement our business plan.
- We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
- Changes in tax laws or regulations could have a material adverse effect on our business and results of operations.
- We could be subject to additional tax liabilities
- Future litigation could have a material adverse effect on our business and results of operations.
Legal proceedings
Arcutis Biotherapeutics, Inc. filed a lawsuit against Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (collectively, Padagis) in the U.S. District Court for the District of Delaware on March 27, 2024, based on the submission to the FDA of an ANDA seeking approval to market and sell a generic version of Arcutis’ ZORYVE® 0.3% cream for the treatment of plaque psoriasis. The Company asserts infringement of the following eleven patents, which are listed in the FDA’s Orange Book for Arcutis’ ZORYVE® 0.3% cream: 9,884,050; 9,907,788; 10,940,142; 11,129,818; 11,793,796; 11,819,496; 11,992,480; 12,005,051; 12,005,052; 12,011,437; and 12,016,848 (collectively, Asserted Patents). Arcutis seeks a judgment that Padagis has infringed or will infringe one or more claims of each of the Asserted Patents and based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Padagis’s proposed generic product before expiration of each of the Asserted Patents found to be infringed.
In March 2025, Arcutis agreed to file a joint stipulation to stay the ongoing patent litigation with Padagis at the request of Padagis. On April 3, 2025, the court stayed the case and cancelled all case deadlines, including the trial. The automatic 30-month stay of FDA approval of Padagis’s ANDA seeking approval for Arcutis’s ZORYVE® 0.3% cream was set to expire on August 14, 2026. The 30-month stay will be extended for each day the stay is in place, starting March 24, 2025, until the stay is lifted.
Teva Pharmaceutical Industries Ltd. filed oppositions with the EPO against two of our European patents in the third quarter of 2024. After oral proceedings for each of the respective patents, the EPO panel found in favor of Arcutis and maintained both patents.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARTodd Franklin Watanabe, Officer
- 19SEC EDGARMasaru Matsuda, See Remark
- 20
- 21
- 22
- 23
- 24SEC EDGARPatrick Burnett, Officer
- 25SEC EDGARChristopher Peetz, Board member
- 26SEC EDGARAmit Munshi, Board member
- 27SEC EDGARNeha Krishnamohan, Board member
- 28SEC EDGARSue-Jean Lin, Board member
- 29SEC EDGARKeith R. Leonard, Board member
- 30SEC EDGARAlexander Asam, Board member
- 31SEC EDGARBhaskar Chaudhuri, Board member
- 32SEC EDGARDaniel Estes, Board member
- 33SEC EDGARJonathan Silverstein, Board member
- 34SEC EDGARJoseph L. Turner, Board member
- 35SEC EDGARPatrick J. Heron, Board member
- 36SEC EDGARRicky Sun, Board member
- 37SEC EDGARTodd Franklin Watanabe, Board member
- 38SEC EDGARJohn W. Smither, Board member
- 39SEC EDGARHalley E. Gilbert, Board member
- 40SEC EDGARHoward G. Welgus, Board member
- 41SEC EDGARTerrie Curran, Board member
- 42SEC EDGARMasaru Matsuda, General counsel
- 43
- 44
- 45SEC EDGARShareholder vote; Other events
- 46SEC EDGARFinancial statements and exhibits
- 47SEC EDGARResults of operations
- 48
- 49SEC EDGARResults of operations
- 50SEC EDGARResults of operations
- 51SEC EDGARShareholder vote; Other events
- 52SEC EDGARResults of operations
- 53
- 54SEC EDGARResults of operations
- 55NasdaqNasdaq calendar
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72